These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7238849)

  • 21. [New chemotherapy in arterial hypertension].
    Chiti E
    Minerva Med; 1971 Nov; 62(84):4143-8. PubMed ID: 5136617
    [No Abstract]   [Full Text] [Related]  

  • 22. Tiamenidine (Hoe 440), a new antihypertensive substance.
    Lindner E; Kaiser J
    Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):305-25. PubMed ID: 4460920
    [No Abstract]   [Full Text] [Related]  

  • 23. [Blood pressure and heart rate of rats after repeated treatment with 2-(2,6-dichlorphenylamino)-2-imidazoline].
    Walland A
    Arzneimittelforschung; 1968 Jul; 18(7):833-6. PubMed ID: 5755830
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
    Zaslavskaia RM; Komarov FI; Shakirova AN; Teĭblium MM; Akhmetov KZh
    Klin Med (Mosk); 2000; 78(4):41-4. PubMed ID: 10833890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride (Catapres) upon the systemic and coronary haemodynamics and metabolism of intact dogs.
    Maxwell GM
    Arch Int Pharmacodyn Ther; 1969 Sep; 181(1):7-14. PubMed ID: 5350786
    [No Abstract]   [Full Text] [Related]  

  • 27. [Acute effects of ST-155, a new antihypertensive agent on cardiac and renal hemodynamics].
    Vorburger C; Bütikofer E; Weiss S; Diacon C
    Helv Med Acta Suppl; 1967 May; 47():133-4. PubMed ID: 5286301
    [No Abstract]   [Full Text] [Related]  

  • 28. Hemodynamic effects of the new inotropic agent sulmazol (AR-L115 BS) administered intravenously to patients with severe heart failure.
    Hagemeijer F; van Mechelen R; Schelling A
    Herz; 1983 Feb; 8(1):41-6. PubMed ID: 6832692
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of acute administration of 2-amino-4-(3,4-dichlorophenyl)-2-imidazoline HBr (MJ 10459-2) or guanethidine on selected sympathetically-mediated responses in the anesthetized dog and cat.
    Deitchman D; Gomoll AW; Snyder RW; Preston JE
    Arch Int Pharmacodyn Ther; 1974 Aug; 210(2):268-78. PubMed ID: 4441194
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute renal excretory actions of losartan in spontaneously hypertensive rats: role of AT2 receptors, prostaglandins, kinins and nitric oxide.
    Munoz-Garcia R; Maeso R; Rodrigo E; Navarro J; Ruilope LM; Casal MC; Cachofeiro V; Lahera V
    J Hypertens; 1995 Dec; 13(12 Pt 2):1779-84. PubMed ID: 8903651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental study of kidney hemodynamics and the behavior of electrolytes after a single administration of 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride].
    Baum P
    Arzneimittelforschung; 1966 Sep; 16(9):1162-5. PubMed ID: 6014735
    [No Abstract]   [Full Text] [Related]  

  • 32. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of hypotensive therapy on central hemodynamics in patients with hypertension].
    Andrushchenko EV; Glukhovskaia GF; Krasovskaia EA; Polishchuk II; Makhfuz AA
    Vrach Delo; 1985 Apr; (4):41-3. PubMed ID: 4013188
    [No Abstract]   [Full Text] [Related]  

  • 35. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH.
    Bamberger CM; Mönig H; Mill G; Gödde E; Schulte HM
    Exp Clin Endocrinol Diabetes; 1995; 103(3):205-8. PubMed ID: 7584524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs.
    Bruban V; Feldman J; Greney H; Dontenwill M; Schann S; Jarry C; Payard M; Boutin J; Scalbert E; Pfeiffer B; Renard P; Vanhoutte P; Bousquet P
    Br J Pharmacol; 2001 May; 133(2):261-6. PubMed ID: 11350862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
    Fruhwald FM; Kjellström B; Perthold W; Wonisch M; Maier R; Klein W
    J Heart Lung Transplant; 2005 May; 24(5):631-4. PubMed ID: 15896766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance].
    Lotti G; Gianrossi R
    Fortschr Med; 1993 Sep; 111(27):429-32. PubMed ID: 8225149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
    Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [On long term treatment of hypertension in ambulatory practice with an imidazoline derivative].
    Schwarz FK; Schwarz MT
    Landarzt; 1968 Feb; 44(4):191-4. PubMed ID: 4976526
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.